AACR 2016: NCI's Center for Cancer Genomics: Initiatives to Further Precision Medicine

Sunday, Apr 17, 2016, 2:15 PM - 3:45 PM
Room 352, Morial Convention Center

The NCI Center for Cancer Genomics (CCG) unifies NCI's activities in cancer genomics by aiming to synthesize research in different fields of cancer genomics – structural, functional, and computational – to advance precision medicine and improve patient outcomes. The Center is innovating across the entire spectrum of cancer genomics: from basic cancer genomics research, development of bioinformatics infrastructure to improve data accessibility, to validating new therapeutic targets and diagnostic and prognostic markers. As a resource for cancer investigators around the world, CCG will help to forge a new era of precision medicine. 

In this session, we will describe initiatives supported by the CCG including programmatic objectives and research highlighting the data, resources and tools openly available to the research community from each program. The speakers will provide an overview of the Center that includes funding opportunities as well as updates on up-and-coming CCG programs. In addition, an overview of lessons learned and data available from innovative CCG tumor characterization initiatives in both adult and pediatric cancers will also be presented. The programs to be discussed include Precision Medicine Trials, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials (ALCHEMIST), Exceptional Responders Initiative, Cancer Driver and Development Program (CDDP), Clinical Trials Sequencing Project (CTSP), Burkitt Lymphoma Genome Sequencing Project (BLGSP), HIV+ Tumor Molecular Characterization Project (HTMCP), Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and The Cancer Genome Atlas (TCGA). The session will also provide an update on the tools and data available through the Cancer Target Development and Discovery (CTD2) initiative which seeks to bridge the gap between the enormous volumes of data generated by the genomic characterization studies and the ability to use these data for the development of human cancer therapeutics. Finally, the session will end with an overview of how to access the comprehensive genomic data generated by CCG initiatives through the new Genomic Data Commons (GDC), which will be released to the public in June 2016.

  • Jaime M. Guidry Auvil. National Cancer Institute-CCG, Bethesda, MD
  • Jean C. Zenklusen. National Cancer Institute-CCG, Bethesda, MD
  • Roy Tarnuzzer. National Cancer Institute-CCG, Bethesda, MD
  • Subhashini Jagu. National Cancer Institute-CCG, Bethesda, MD
  • Zhining Wang. National Cancer Institute, Bethesda, MD

For more information, visit the AACR Website.